Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, has announced the appointment of Brent Shafer and Tom Miller, Ph.D., to its board of directors, effective immediately. Mr. Shafer, with over 40 years of experience in healthcare technologies, will serve on the Compensation Committee. Dr. Miller, a scientist and entrepreneur focusing on AI, chemistry, and biology, will join the Regulatory and Compliance Committee.
Mr. Shafer's background includes roles as chairman and CEO of Cerner and CEO of Philips North America. Dr. Miller is the co-founder and CEO of Iambic Therapeutics and a former tenured professor at Caltech. Both new board members expressed enthusiasm for Veracyte's mission and potential impact on cancer diagnostics and patient care.
Veracyte, Inc. (Nasdaq: VCYT), un'azienda leader nel settore della diagnostica oncologica, ha annunciato la nomina di Brent Shafer e Tom Miller, Ph.D. nel suo consiglio di amministrazione, con effetto immediato. Il signor Shafer, con oltre 40 anni di esperienza nelle tecnologie sanitarie, farà parte del Comitato Risorse Umane. Il dottor Miller, scienziato e imprenditore con un focus su IA, chimica e biologia, si unirà al Comitato Regolamentare e di Conformità.
Il background del signor Shafer include ruoli come presidente e CEO di Cerner e CEO di Philips Nord America. Il dottor Miller è co-fondatore e CEO di Iambic Therapeutics ed è stato professore ordinario al Caltech. Entrambi i nuovi membri del consiglio hanno espresso entusiasmo per la missione di Veracyte e il potenziale impatto nella diagnostica oncologica e nella cura dei pazienti.
Veracyte, Inc. (Nasdaq: VCYT), una empresa líder en diagnósticos de cáncer, ha anunciado el nombramiento de Brent Shafer y Tom Miller, Ph.D. en su junta directiva, con efecto inmediato. El señor Shafer, con más de 40 años de experiencia en tecnologías de salud, formará parte del Comité de Compensación. El Dr. Miller, científico y empresario enfocado en IA, química y biología, se unirá al Comité Regulador y de Cumplimiento.
La trayectoria del señor Shafer incluye roles como presidente y CEO de Cerner y CEO de Philips Norteamérica. El Dr. Miller es cofundador y CEO de Iambic Therapeutics y fue profesor titular en Caltech. Ambos nuevos miembros de la junta expresaron su entusiasmo por la misión de Veracyte y el posible impacto en los diagnósticos de cáncer y la atención al paciente.
Veracyte, Inc. (Nasdaq: VCYT)은 대표적인 암 진단 회사로, Brent Shafer와 Tom Miller, Ph.D.를 이사로 임명했다고 발표했습니다. 두 사람은 즉시 이사회의 일원이 됩니다. Shafer 씨는 40년 이상의 의료 기술 경험을 가진 인물로 보상위원회에서 활동할 것입니다. Miller 박사는 인공지능, 화학 및 생물학에 초점을 맞춘 과학자이자 기업가로, 규제 및 준수 위원회에 합류합니다.
Shafer 씨의 배경은 Cerner의 회장 및 CEO와 Philips 북미의 CEO를 포함하고 있습니다. Miller 박사는 Iambic Therapeutics의 공동 창립자이자 CEO이며, Caltech의 전임 교수였습니다. 새로 선임된 두 이사는 Veracyte의 사명과 암 진단 및 환자 치료에 미칠 잠재적 영향에 대해 열정을 표현했습니다.
Veracyte, Inc. (Nasdaq: VCYT), une entreprise leader dans le domaine des diagnostics du cancer, a annoncé la nomination de Brent Shafer et Tom Miller, Ph.D. à son conseil d'administration, avec effet immédiat. M. Shafer, qui possède plus de 40 ans d'expérience dans les technologies de la santé, siégera au Comité de Rémunération. Le Dr Miller, scientifique et entrepreneur axé sur l'IA, la chimie et la biologie, rejoindra le Comité de Réglementation et de Conformité.
Le parcours de M. Shafer comprend des rôles en tant que président et CEO de Cerner et CEO de Philips Amérique du Nord. Le Dr Miller est cofondateur et CEO de Iambic Therapeutics et a été professeur titulaire au Caltech. Les deux nouveaux membres du conseil ont exprimé leur enthousiasme pour la mission de Veracyte et l'impact potentiel sur les diagnostics du cancer et les soins aux patients.
Veracyte, Inc. (Nasdaq: VCYT), ein führendes Unternehmen in der Krebsdiagnostik, hat die Ernennung von Brent Shafer und Tom Miller, Ph.D. in seinen Vorstand bekannt gegeben, die sofort in Kraft tritt. Herr Shafer, der über 40 Jahre Erfahrung in Gesundheitstechnologien verfügt, wird im Vergütungsausschuss tätig sein. Dr. Miller, ein Wissenschaftler und Unternehmer mit Fokus auf KI, Chemie und Biologie, wird dem Ausschuss für Regulierungsangelegenheiten und Compliance beitreten.
Die Erfahrung von Herrn Shafer umfasst Positionen als Vorsitzender und CEO von Cerner und CEO von Philips Nordamerika. Dr. Miller ist Mitbegründer und CEO von Iambic Therapeutics und war Professor an der Caltech. Beide neuen Vorstandsmitglieder äußerten ihre Begeisterung für die Mission von Veracyte und den potenziellen Einfluss auf die Krebsdiagnostik und die Patientenversorgung.
- Addition of two experienced healthcare industry leaders to the board of directors
- Broadening of board expertise in health information technologies and AI-driven drug discovery
- Potential for accelerated growth and innovation with new board members' insights
- None.
New Veracyte board member Brent Shafer. (Photo: Business Wire)
“We are thrilled to welcome Brent and Tom to our board,” said Marc Stapley, Veracyte’s chief executive officer. “They are both seasoned business leaders with extensive healthcare industry experience who will further broaden our board’s mix of backgrounds and expertise.”
Mr. Shafer brings over 40 years of experience across health information technologies, medical devices and a variety of healthcare solutions to the company. He previously served as chairman and CEO of Cerner Corporation and CEO of Philips North America and Philips Home Healthcare Solutions. Before that, he served in a variety of roles at Hillrom, GE Medical Systems and Johnson & Johnson. Upon joining the board, Mr. Shafer will also serve as a member of the Compensation Committee.
Dr. Miller is a scientist and entrepreneur with a focus on the nexus of AI, chemistry and biology. He co-founded and serves as CEO of Iambic Therapeutics, a biotechnology company that is disrupting the therapeutics landscape with an AI-driven, drug-discovery platform. Prior to that, he spent over 10 years as a tenured professor at Caltech, publishing more than 140 peer-reviewed articles and patents. Upon joining the board, Dr. Miller will also serve as a member of the Regulatory and Compliance Committee.
“I am thrilled to join the Veracyte board to support the management team in advancing their vision,” said Mr. Shafer. “I look forward to leveraging my experience to help accelerate the momentum underway at Veracyte with their focus on empowering physicians with the high-value insights they need to best serve patients.”
“It’s an honor to be a part of a company with such a compelling platform and that is so well-positioned to positively impact the journey of so many cancer patients,” said Dr. Miller. “I am particularly excited by the company’s increased investment in AI as part of their focus on helping clinicians, researchers and patients gain even further ground on cancer.”
About Veracyte
Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com and follow the company on X (formerly Twitter) at @veracyte.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, and expectations (financial and otherwise) or our intentions with respect to our tests and products, for use in diagnosing and treating diseases, in and outside of
Veracyte, the Veracyte logo, and Decipher are registered trademarks of Veracyte, Inc., and its subsidiaries in the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904531409/en/
Investors:
Shayla Gorman
investors@veracyte.com
619-393-1545
Media:
Tracy Morris
media@veracyte.com
650-380-4413
Source: Veracyte, Inc.
FAQ
Who are the new board members appointed by Veracyte (VCYT)?
What is Brent Shafer's background and role on Veracyte's (VCYT) board?
What is Tom Miller's expertise and position on Veracyte's (VCYT) board?
How might these new board appointments impact Veracyte's (VCYT) future direction?
